AI-generated analysis. Always verify with the original filing.
Lantern Pharma filed an 8-K on March 30, 2026 disclosing its 2025 full year and Q4 financial results and key operational updates.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
, including Exhibit 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
Financial Statements and Exhibits.** (d) Exhibits . | Exhibit No. | | Exhibit Description | |---|---|---| | | | | | 99.1 | | Press Release dated March 30, 2026
| Metric | Value | Basis |
|---|---|---|
| Total Operating Expenses | 19% |